Headline
The latest stories from AHA Today.
In a study reported in JAMA Network Open, rural hospital mergers were associated with lower mortality for patients admitted to the hospital for heart attack, heart failure, stroke and pneumonia.
Johnson & Johnson said its phase 3 trial data confirms its vaccine’s durability and provided evidence of a second, booster shot’s effectiveness against COVID-19.
The House is expected to consider a continuing resolution that would generally extend current federal funding levels for health care and all other programs through Dec. 3.
U.S. hospitals will lose an estimated $54 billion in net income this year, even after federal relief funds, as higher labor and other expenses and sicker patients impact their financial health during the ongoing COVID-19 pandemic, according to a report by Kaufman, Hall & Associates released by…
The Brigham Comprehensive Opioid Response and Education program and McLean Hospital of Belmont, Mass., on Sept. 21 at 12 p.m. ET will host a town hall virtual event, during which experts and those with experience with substance misuse and treatment will discuss COVID-19’s impact on these…
The Centers for Medicare & Medicaid Services awarded 20 states American Rescue Plan Act grants to develop and implement mobile crisis intervention services for people experiencing a substance use-related or mental health crisis.
President Biden added measles to the list of quarantinable diseases, as recommended by Health and Human Services Secretary Xavier Becerra and Surgeon General Vivek Murthy, M.D.
The Food and Drug Administration authorized administering the monoclonal antibodies bamlanivimab and etesevimab together to prevent COVID-19 in certain children and adults exposed to SARS-CoV-2 who are not fully vaccinated against COVID-19 and at high-risk for progressing to severe disease.
The Food and Drug Administration alerted clinical laboratory staff and health care providers to the potential for false positive results with two test kits made by Abbott Molecular to detect SARS-CoV-2.
Pfizer released the first data evaluating a COVID-19 vaccine’s safety and effectiveness for children between the ages of 5 and 11.